motexafin gadolinium + rituximab + ibritumomab tiuxetan

This is a **combination regimen** consisting of motexafin gadolinium (a redox-active metalloporphyrin and radiosensitizer), rituximab (a chimeric monoclonal antibody against CD20), and ibritumomab tiuxetan (a radiolabeled monoclonal antibody targeting CD20, typically conjugated to the radioisotope yttrium-90). Motexafin gadolinium inhibits thioredoxin reductase, depletes cellular antioxidants, and enhances tumor cell sensitivity to radiation and chemotherapy[1][7][5][9]. Rituximab mediates elimination of CD20+ B lymphocytes through complement-dependent cytotoxicity and antibody-dependent cellular cytotoxicity[8][6]. Ibritumomab tiuxetan delivers targeted radiation to CD20+ B lymphocytes, causing localized cytotoxicity, and is effective in lymphoma refractory to rituximab[6][8]. This triple regimen is investigational, with combination use explored for the treatment of certain lymphomas and brain metastases, but not as a marketed single agent or approved therapeutic combination.

Other names

motexafin gadoliniumrituximabibritumomab tiuxetan90Y-ibritumomab tiuxetan